Caris Life Sciences, Inc. (CAI) income statement
CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3090% above fair value
$19.50−0.44 (-2.21%)
Close on Nov 18, 2026Market cap $5.51BP/E –Yield –
Caris Life Sciences, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- 13.4%
- Net margin
- 9.2%
- Return on equity, FY2025
- 7.1%
Financial strength
- Current ratio
- 6.71
- Debt to equity
- 0.61
- Debt to assets
- 31.3%
- Cash to current liabilities
- –
Valuation
- P/E ratio
- –
- Price to sales
- 5.26
- Price to book
- 8.62
- Dividend yield
- –
See a number that looks wrong?